Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel.
about
Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basisA discriminative analytical method for detection of CES1A1 and CES1A2/CES1A3 genetic variantsChemical analysis and transplacental transfer of oseltamivir and oseltamivir carboxylic acid in pregnant ratsIndividualization of treatments with drugs metabolized by CES1: combining genetics and metabolomics.Structure-Activity Relationships of Pentacyclic Triterpenoids as Potent and Selective Inhibitors against Human Carboxylesterase 1Evaluation of [(11)C]oseltamivir uptake into the brain during immune activation by systemic polyinosine-polycytidylic acid injection: a quantitative PET study using juvenile monkey models of viral infectionAge-related inducibility of carboxylesterases by the antiepileptic agent phenobarbital and implications in drug metabolism and lipid accumulation.Oseltamivir treatment prevents the increased influenza virus disease severity and lethality occurring in chronic ethanol consuming miceSpecificity of a prodrug-activating enzyme hVACVase: the leaving group effectSurge in expression of carboxylesterase 1 during the post-neonatal stage enables a rapid gain of the capacity to activate the anti-influenza prodrug oseltamivir.Effects of alcohol on human carboxylesterase drug metabolism.Analysis of a child who developed abnormal neuropsychiatric symptoms after administration of oseltamivir: a case report.Hypolipidemic agent Z-guggulsterone: metabolism interplays with induction of carboxylesterase and bile salt export pumpSpecies-dependent uptake of glycylsarcosine but not oseltamivir in Pichia pastoris expressing the rat, mouse, and human intestinal peptide transporter PEPT1.The role of human carboxylesterases in drug metabolism: have we overlooked their importance?A population-based study of the drug interaction between clopidogrel and angiotensin converting enzyme inhibitors.Substrate-Competitive Activity-Based Profiling of Ester Prodrug Activating EnzymesAn improved synthesis of a fluorophosphonate-polyethylene glycol-biotin probe and its use against competitive substrates.Sacubitril Is Selectively Activated by Carboxylesterase 1 (CES1) in the Liver and the Activation Is Affected by CES1 Genetic Variation.Regulatory effects of genomic translocations at the human carboxylesterase-1 (CES1) gene locus.CES1P1 variant -816A>C is not associated with hepatic carboxylesterase 1 expression and activity or antihypertensive effect of trandolapril.The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel responseLow penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteersStructure and catalytic properties of carboxylesterase isozymes involved in metabolic activation of prodrugs.Pharmacokinetics of high-dose oseltamivir in healthy volunteers.Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin.Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hydrolase (FAAH).Pyrethroid insecticides: isoform-dependent hydrolysis, induction of cytochrome P450 3A4 and evidence on the involvement of the pregnane X receptor.Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system.Quantitative proteomic analysis of hepatocyte-secreted extracellular vesicles reveals candidate markers for liver toxicityNuclear receptor-mediated regulation of carboxylesterase expression and activity.A comparison of the metabolism of clopidogrel and prasugrel.Carboxylesterase inhibitors.Effect of oseltamivir on bleeding risk associated with warfarin therapy: a retrospective review.Post-marketing assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: an updated review.Pharmacokinetic properties of anti-influenza neuraminidase inhibitors.Combinatorial and sequential delivery of gemcitabine and oseltamivir phosphate from implantable poly(d,l-lactic-co-glycolic acid) cylinders disables human pancreatic cancer cell survival.Selective Inhibitors of Human Liver Carboxylesterase Based on a β-Lapachone Scaffold: Novel Reagents for Reaction Profiling.Tumour-selective targeting of drug metabolizing enzymes to treat metastatic cancerEfficient in vitro refolding and functional characterization of recombinant human liver carboxylesterase (CES1) expressed in E. coli.
P2860
Q24655643-4C10FF6C-1807-4B15-9E5B-CB17269D08E0Q28257265-94748860-8389-456C-A6F0-8998DC73BEB9Q28484222-85153C0A-43F9-436C-9D19-3D3AD1A73152Q30373969-5F4A26D4-5301-4490-A322-BAF471989219Q33854828-C8874A8A-4658-48A8-8E3B-242074E35E97Q33909405-6553CE1D-47DD-4F9E-B6C1-E3D3862B6E09Q33935727-787CB8B4-BCCC-42EE-BDFB-321AC58D534FQ34020714-06E8E3D1-133F-4869-8E93-26AFC87A3DF0Q34384533-F775C2A4-6AC4-4029-8A81-81F8B5CDBE72Q34743315-DC7F6E26-993E-4C42-95F6-B5B48AF71737Q35668517-3A4D45C6-7982-472B-B8A0-D9F65997DC35Q35737905-E3B97649-751B-43C4-84DF-C5BE74FB7386Q35747799-ABE48BCA-8696-4C46-BF54-B53EF737DD03Q36057398-06CCC32E-451D-4A34-B0AC-DA782DE4E04AQ36066647-AE4E8044-749B-4722-B8C5-47B00A24CFB6Q36125455-1D90ACAE-ADC6-4344-B680-AF7AF0E3F363Q36412505-D23B214A-656A-4693-9FC6-B53021955804Q36594217-D70597F9-08CC-4ADC-8672-C422F84A4B98Q36736998-98225B90-8185-4120-A02D-DE0DFF877271Q36767978-032F669E-726D-43DD-880A-C5048E0B2ED2Q36896568-7A110E9E-1B75-4B81-9375-85BB10AB6843Q36928556-09D0905C-171F-4520-B1D6-AF801E51594DQ36932915-0BD8EABF-5CE3-4B1C-991D-68DE44DA2F4FQ37096508-4399C725-7019-4F1B-A84A-772F75A28A58Q37115683-DA2D2577-2DE8-494D-8575-C8F566D538A3Q37163881-267C004E-46BC-4883-BA7B-68DE2CF8148CQ37287291-5C64353A-9CB0-4E6E-85F3-A55FF2D5DA9FQ37308959-5C7B9E94-1A96-45B0-B167-1CAD6A3ECA59Q37409972-4FBCEAC1-F672-441E-9499-1AADF2D049FCQ37428949-5E2E8504-28B6-4897-905E-753E925D007AQ37693954-2A333C0B-5D5A-4D56-8327-A71036AC073FQ37788682-24686DAD-8AAC-4744-B142-47237B8983C5Q37879148-3ED99EA6-AA94-4271-9065-3F5CBCC68E2FQ37965570-7DEAE887-7693-4DB9-9F3E-5E8259797069Q38051213-95ED0250-C31B-49D8-A767-DD14AD00AB80Q38084212-80E0EB45-E13F-46B0-8170-B7599E86D758Q38694772-8F485937-141B-4180-A7AC-B7326D3D2973Q38719965-D7592DDD-91F8-49FD-B682-4CABCB52342AQ38898663-52671E4F-C83E-49CA-920D-6AC4691D87D5Q38914678-AA407AA9-E80E-481B-BE3A-0416035AF1EB
P2860
Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel.
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Anti-influenza prodrug oseltam ...... ntiplatelet agent clopidogrel.
@ast
Anti-influenza prodrug oseltam ...... ntiplatelet agent clopidogrel.
@en
type
label
Anti-influenza prodrug oseltam ...... ntiplatelet agent clopidogrel.
@ast
Anti-influenza prodrug oseltam ...... ntiplatelet agent clopidogrel.
@en
prefLabel
Anti-influenza prodrug oseltam ...... ntiplatelet agent clopidogrel.
@ast
Anti-influenza prodrug oseltam ...... ntiplatelet agent clopidogrel.
@en
P2093
P356
P1476
Anti-influenza prodrug oseltam ...... antiplatelet agent clopidogrel
@en
P2093
Bingfang Yan
Chris Black
Dongfang Yang
Fatemeh Akhlaghi
P304
P356
10.1124/JPET.106.111807
P407
P577
2006-09-11T00:00:00Z